Pharmacokinetic Modeling and Half-Life

Pharmacokinetic modelling represents the time course of drug concentrations with mathematical descriptions, from simple compartmental models to mechanistic physiologically based (PBPK) models. The elimination half-life - the time for the plasma concentration to fall by half - is a derived parameter summarising how quickly a drug leaves the body. Modelling and half-life together let pharmacokinetic data be condensed into parameters that describe and predict drug behaviour.

Definition

Pharmacokinetic modelling is the mathematical representation of the time course of drug concentrations; the elimination half-life is the time required for the plasma concentration (or amount of drug in the body) to decrease by one half during the terminal phase, related to clearance and volume of distribution by t-half equals 0.693 times Vd divided by clearance.

Scope

This topic covers compartmental and physiologically based pharmacokinetic modelling, the meaning and derivation of half-life from clearance and volume of distribution, and the use of models to predict exposure and accumulation. It is presented as a quantitative and methodological topic and does not provide dosing recommendations.

Core questions

• How can the time course of drug concentration be described mathematically?
• How is half-life derived from clearance and the volume of distribution?
• When are compartmental versus physiologically based models appropriate?

Key concepts

• Elimination half-life
• First-order (exponential) elimination
• One- and multi-compartment models
• Terminal elimination phase
• Accumulation and time to steady state
• Physiologically based pharmacokinetic (PBPK) models
• In vitro-in vivo extrapolation (IVIVE)
• Relationship t-half = 0.693 x Vd / CL

Key theories

Compartmental pharmacokinetic models

Drug disposition is represented by one or more kinetically homogeneous compartments with first-order transfer and elimination, yielding exponential concentration-time curves from which half-life and other parameters are estimated; this empirical framework was codified as the classical basis of pharmacokinetic analysis.

Physiologically based pharmacokinetic (PBPK) modelling

PBPK models represent the body as physiological compartments connected by blood flow, parameterised by organ volumes, perfusion, and in vitro drug data, enabling mechanistic prediction of disposition and extrapolation across populations and species.

Mechanisms

When elimination is first-order, drug concentration declines exponentially, and the time for it to halve - the half-life - is constant regardless of the starting concentration. The half-life is not an independent property but a consequence of the two primary parameters: it lengthens as the volume of distribution grows and shortens as clearance increases, following t-half equals 0.693 times Vd over clearance. Compartmental models fit such exponential curves to data to estimate these parameters, while physiologically based models build the concentration-time profile from organ volumes, blood flows, and in vitro measures of metabolism and binding, allowing prediction before human data exist (Jones, 2009; Rostami-Hodjegan, 2007). Half-life also governs how a drug accumulates: roughly four to five half-lives are needed to approach steady state on repeated dosing. Empirical parameter ranges across many drugs inform and validate such models (Obach, 2008).

Clinical relevance

Half-life conceptually indicates how long a drug persists, how often it might need to be given to maintain exposure, and how long accumulation or washout takes, while models support prediction of these behaviours. This entry explains the parameters and modelling approaches at a reference level and is not a source of dosing schedules or individualised advice.

Evidence & guidelines

Physiologically based pharmacokinetic modelling is increasingly used in drug development and accepted by regulators to support predictions of drug-drug interactions and exposure in special populations, when adequately verified (Rostami-Hodjegan, 2007; Jones, 2009). Compendia of measured human pharmacokinetic parameters provide the reference data against which model predictions of clearance, volume, and half-life are evaluated (Obach, 2008).

History

Compartmental pharmacokinetics developed through the twentieth century as the mathematical description of drug concentration-time data, codified in monographs such as Gibaldi and Perrier (1982) and Rowland and Tozer's texts. From the 2000s, physiologically based modelling and in vitro-in vivo extrapolation grew into mainstream tools for predicting human pharmacokinetics from preclinical and in vitro data, extending modelling from description toward prospective prediction (Rostami-Hodjegan, 2007; Jones, 2009).

Key figures

• Milo Gibaldi
• Donald Perrier
• Malcolm Rowland
• Thomas Tozer
• Amin Rostami-Hodjegan
• Geoffrey Tucker

Seminal works

• gibaldi-perrier-1982
• rostami-hodjegan-2007
• jones-2009

Frequently asked questions

What is a drug's half-life?

The elimination half-life is the time it takes for the concentration of a drug in plasma to fall by half during the terminal elimination phase. It reflects how quickly the body removes the drug and depends on both clearance and the volume of distribution.

What is the difference between compartmental and PBPK modelling?

Compartmental models are empirical: they fit one or more abstract compartments to concentration-time data. Physiologically based (PBPK) models are mechanistic: they represent real organs connected by blood flow and use physiological and in vitro data to predict drug disposition, including before human data are available.